SAM, Goodwin, Saraf, Cravath advice on India biopharma deal
As a result of their work together, Shardul Amarchand Mangaldas & Co. and Goodwin Procter advised Biocon Biologics, a subsidiary
SAM, Goodwin, Saraf, Cravath advice on India biopharma dealAs a result of their work together, Shardul Amarchand Mangaldas & Co. and Goodwin Procter advised Biocon Biologics, a subsidiary of Indian drugmaker Biocon, on its $3.34 billion acquisition of the biosimilars business of American firm Viatris, which was advised by Cravath, Swaine & Moore and Saraf and Partners. Reuters...
SAM, Goodwin, Saraf, Cravath advice on India biopharma deal
As a result of their work together, Shardul Amarchand Mangaldas & Co. and Goodwin Procter advised Biocon Biologics, a subsidiary of Indian drugmaker Biocon, on its $3.34 billion acquisition of the biosimilars business of American firm Viatris, which was advised by Cravath, Swaine & Moore and Saraf and Partners.
Reuters reports that Biocon will extend its biosimilars portfolio to 20 treatments by including treatments for diabetes, tumors and autoimmune diseases and commercializing them for developed markets.
In addition, Viatris will receive up to $2.34 billion in cash and convertible shares in Biocon Biologics worth $1 billion, according to Reuters.
Partners Iqbal Khan and Ambarish are leading the SAM team, while partners Graham Defries and Michael R. Patrone lead the Goodwin Procter team. Saraf and Partners was led by partner Mohit Saraf and Cravath was led by partners Mark Greene and Aaron Gruber.